title: [Research of fibronectin, p53 and Ezrin protein with occurrence, progress and prognosis in the primary laryngeal carcinoma by the tissuechip technology].
abstract: OBJECTIVE
  To evaluate the predictive role of fibronectin, p81 (Ezrin protein) and p53 gene in primary laryngeal carcinoma, it's relationship with epidemiology(smoking), histological grading, surgical treatment, TNM stage and prognosis were studied by the tissuechip technology.
  
  
  METHODS
  The expression of fibronectin, p53 gene and p81 (Ezrin protein) on a series of 85 primary laryngeal carcinoma patients treated in our hospital between 1992 and 2000 was studied with tissuechip technology. The correlation of each score according to the intensity and percentage of labeled cells or intercellular substance with relevant clinical dada was statistically analyzed.
  
  
  RESULTS
  Some cases were lost or boosted no tumor tissue in our tissuechip. Among the 70 cases available, 45.71% (32/70) of the specimens' basal membrane and extracellular matrix were strongly stained with fibronectin; there is statistical significance (P < 0.05) between primary tumor grading groups. Ezrin protein expressing rate is 87.3%, and the average percentage of its labeled cells is 53.68% (ranging from 0% to 100%, median is 58. 69%). There were significant difference between tumor grading groups, clinical early and late stages and 3-year survival rates (P < 0.05) after chi-square test. But no relation with smoking, gender, age and histological classes (P > 0.05). The average percentage of p53 positive cells is 21.6% (ranging from 0% to 90.3%, median is 5.85%) and 46.8% showed positive stains in our research. There was no statistical prominence in p53 protein demonstration between TNM stages, lymph node metastasis, 3-year survival rate, smoking, gender, age and histological classes (P > 0.05).
  
  
  CONCLUSIONS
  The tissue microarray technique spent shorter time and less expense, and showed higher consistency in our essays. And the present study suggests fibronectin and p81 (Ezrin protein) could be the clinical discriminators in laryngeal carcinoma.
authors.affiliation: Department of Otorhinolaryngology-Head & Neck Surgery, Shanghai First People's Hospital of Shanghai Jiao Tong University, Shanghai, China. dongpin64@yahoo.com.cn
authors.forename: Pin
authors.initials: P
authors.lastname: Dong
authors.forename: Xiao-yan
authors.initials: XY
authors.lastname: Li
authors.forename: Guang-zhong
authors.initials: GZ
authors.lastname: Lu
authors.forename: Zheng-hua
authors.initials: ZH
authors.lastname: Zhu
authors.forename: Zi-wei
authors.initials: ZW
authors.lastname: Yu
authors.forename: Bin
authors.initials: B
authors.lastname: Jin
authors.forename: Jiang-cai
authors.initials: JC
authors.lastname: Zhu
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D002294:Carcinoma, Squamous Cell / Q000378:metabolism* / Q000473:pathology; D003598:Cytoskeletal Proteins / Q000378:metabolism*; D005260:Female; D005353:Fibronectins / Q000378:metabolism*; D006801:Humans; D007822:Laryngeal Neoplasms / Q000378:metabolism* / Q000473:pathology; D008207:Lymphatic Metastasis; D008297:Male; D008875:Middle Aged; D060787:Neoplasm Grading; D011379:Prognosis; D016159:Tumor Suppressor Protein p53 / Q000378:metabolism*; D000099149:Ezrin
chemical_list: D003598:Cytoskeletal Proteins; D005353:Fibronectins; D016159:Tumor Suppressor Protein p53; D000099149:Ezrin; C495901:TP53 protein, human